Formulation Featured Articles
-
The Expanding Patent Landscape For RNA-Based Therapeutics
11/16/2022
The COVID-19 pandemic thrust RNA-based therapeutics into the spotlight. Before that, only a handful had received regulatory approval. Why are RNA-based therapeutics seeing more patent activity now and how should biotech companies mitigate patent risks? Attorneys from Neal Gerber Eisenberg share their insights.
-
Strategies To Overcome Delays In The Development Of Genomic Medicines
10/13/2022
Learn how optimizing LNPs can help overcome drug-delivery challenges, unlocking potential new genomic medicines in a shorter time.
-
mRNA-Lipid Nanoparticles Circumvent Viral Vector Limitations
6/1/2022
Both physical and chemical nonviral gene delivery systems for ex vivo genetic modification offer advantages over viral vectors, including smaller scale production and the low risk of immunogenicity.
-
FDA Releases Draft Guidance On CMC For Individualized ASO Therapies
4/26/2022
A new FDA guidance released in Dec. 2021 acknowledges the difficulties inherent in manufacturing individualized antisense oligonucleotide (ASO) treatments and offers researchers and manufacturers the opportunity to create policies and procedures that are more likely to be condoned by the FDA in an IND submission.
-
The Current Landscape Of mRNA Vaccines In Clinical Research
3/17/2022
With the Pfizer-BioNTech and Moderna products, mRNA vaccines made global headlines in 2021 in the fight against COVID-19. As we recognize National Immunization Awareness Month, this article shares how mRNA vaccines currently in clinical research and clinical trials may be soon used to fight HIV-1, herpes, cancer, and more.
-
Translation Of RNA Medicines From Design To Clinic
3/2/2022
Understand the advantages and challenges of lipid-based delivery systems for successful translation of RNA into clinical development.
-
How mRNA Technology Is Shaping The Future Of Medicine
1/4/2022
Discover how mRNA technologies open the doors to a whole range of new gene therapies and the role of lipid nanoparticles (LNPs) in current and future developments.
-
Are Dry Powder Biologics Ready For Primetime?
9/21/2020
A new approach to freezing biopharmaceuticals into fine, dry powders holds promise for flexible therapeutic form factors, efficacy improvements, and supply and distribution chain efficiencies. It's a particularly timely development in the age of COVID-19.
-
FrymaKoruma At Interphex 2013 Highly Flexible And Hygienic Processes
3/11/2013
The FrymaKoruma MZ toothed colloid mill will be the centrepiece of the Romaco FrymaKoruma exhibit at this year’s Interphex in New York (USA). This milling system is used for wet grinding of suspensions and other products of almost any viscosity.
-
Comparison Of Air-Wheel Bioreactor Against The Traditional Stirred-Tank Bioreactor in Microcarrier Applications
1/29/2013
A novel bioreactor system from PBS Biotech utilizes the patented Air-Wheel technology to promote uniform and homogenous liquid mixing and offers a low shear environment for cell culture.